Results 181 to 190 of about 326,443 (336)

Mannose‐Modified Cationic Liposome‐Based mRNA Therapeutics for Improved Triple‐Negative Breast Cancer Immunotherapy

Advanced NanoBiomed Research, EarlyView.
Schematic illustration of mTEM8‐loaded cationic liposome (cLipo‐Man/mTEM8) therapeutics for improved triple‐negative breast cancer immunotherapy. Despite triple‐negative breast cancer (TNBC) is the most heterogeneous and aggressive subtype of breast cancer, immunotherapy is emerging as a promising therapy.
Kexin Deng, Juping Sun, Junyu Liu, Yuqi Zhang, Wanwan Liu, Xiaobin Li, Han Wu, Juan Li, Jisong Zhang, Chanyuan Jin, Can Yang Zhang   +10 more
wiley   +1 more source

Targeted photodynamic therapy of breast cancer cells using antibody–phthalocyanine–gold nanoparticle conjugates [PDF]

, 2011
Cook, MJ, Edwards, DR, Moreno, M, Russell, DA, Stuchinskaya, T   +4 more
core   +1 more source

Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells

, 2019
Senem Noyan, Hakan Gürdal, Bala Gür Dedeoğlu   +2 more
openalex   +1 more source

Clinical, pathological and molecular predictors of Fulvestrant long-term benefit in Hormone Receptor-positive / HER2 negative advanced breast cancer [PDF]

, 2022
Rosalba Torrisi, Valentina Vaira, Laura Giordano, Annarita Destro, Vera Basilico, Saveria Mazzara, Piermario Salvini, Gabriella Gaudioso, Bethania Fernandes, Noemi Rudini, Giovanna Masci, Armando Santoro   +11 more
openalex   +1 more source

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

, 2022
Funda Meric‐Bernstam, Muralidhar Beeram, Erika Hamilton, Do‐Youn Oh, Diana L. Hanna, Yoon‐Koo Kang, Elena Elimova, Jorge Chaves, Rachel Goodwin, Jeeyun Lee, Lisle Nabell, Sun Young Rha, José Mayordomo, Anthony B. El-Khoueiry, Shubham Pant, Kanwal Pratap Singh Raghav, Jin Won Kim, Amita Patnaik, Todd Gray, R. H. Davies, Mark A. Ozog, Joseph Woolery, Keun‐Wook Lee   +22 more
openalex   +2 more sources

Serum HER2 extracellular domain as a predictive biomarker for trastuzumab deruxtecan treatment response in HER2-positive gastric cancer: a real-world study. [PDF]

Therap Adv Gastroenterol
Narita Y, Kumanishi R, Takahashi K, Masuishi T, Taniguchi H, Kadowaki S, Honda K, Ando M, Fukui T, Tajika M, Muro K.   +10 more
europepmc   +1 more source

Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. [PDF]

Cancer Chemother Pharmacol
Ji X, Yang Y, Ma C, Huang W, Guo S, Wang L, Zheng H, Wu X.   +7 more
europepmc   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Human epidermal growth factor receptor 2 expression in gynecologic serous carcinomas and preliminary analysis of its characteristics in patients post-neoadjuvant chemotherapy. [PDF]

Front Oncol
Liu L, Cheng N, Kong F, Shen D.
europepmc   +1 more source